Patients who have had immunotherapy, chemotherapy or radiotherapy within  days prior to the first dose of navitoclax, or prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last  weeks prior to first dose of dabrafenib and/or trametinib; chemotherapy regimens without delayed toxicity within the last  weeks preceding the first dose of study treatment; biologics will not be allowed within  days prior to, or during, navitoclax administration
Participants receiving any other investigational agents within  weeks of the start of this trial and throughout the duration of this trial; participants receiving anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) within  weeks prior to first dose of dabrafenib or trametinib; participants receiving proteasome inhibitors or immunomodulatory drugs (imid), or chemotherapy without delayed toxicity within  weeks prior to first dose of dabrafenib or trametinib; treatment by localized radiotherapy is not an exclusion criterion if an interval of at least two weeks between the end of radiotherapy and initiation of protocol therapy is observed
Prior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy, or investigational treatment) within the last  weeks, or chemotherapy without delayed toxicity within the last  weeks preceding the first dose of the combination; prior systemic treatment in the adjuvant setting is allowed
Prior systemic anti-cancer treatment (chemotherapy, immunotherapy, biologic therapy, vaccine therapy or investigational treatment within  weeks preceding first dose of study treatment, or chemotherapy without delayed toxicity within  weeks preceding first dose of study treatment
Systemic anti-cancer therapy within  weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity and any prior immunotherapy approach,  weeks is indicated as washout period
Prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last  weeks; chemotherapy regimens without delayed toxicity within the last  weeks preceding the first dose of study treatment
Prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last  weeks; chemotherapy regimens without delayed toxicity within the last  weeks preceding the first dose of study treatment
Prior systemic anti-cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or vaccine therapy) within the last  weeks; chemotherapy regimens without delayed toxicity within the last  weeks preceding the first dose of study treatment
Systemic anti-cancer therapy within  weeks of the first dose of study treatment. For cytotoxic agents that have major delayed toxicity and washout period is  weeks; prior immunotherapy - washout is  weeks
Systemic anti-cancer therapy within  weeks of the first dose of study treatment. For cytotoxic or immunotherapy agents that can present with major delayed toxicity (eg, anti-CTLA-),  weeks is indicated as washout period
Cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last  weeks, or chemotherapy without delayed toxicity within the last  weeks, preceding the first dose of study medication.
Anti-cancer therapy or investigational anti-cancer therapy or chemotherapy without delayed toxicity within treatment specific timeframe.
Cancer therapy (chemotherapy with delayed toxicity, extensive radiation therapy, immunotherapy, biologic therapy, or major surgery) or investigational anti-cancer drugs within the last  weeks, or chemotherapy without delayed toxicity within the last  weeks, preceding the first dose of study treatment.
Cancer therapy (chemotherapy with delayed toxicity, radiation therapy, immunotherapy, biologic therapy, or major surgery) within the last  weeks; chemotherapy regimens without delayed toxicity within the last  weeks; or use of any investigational anti-cancer or other drug within  days or  half-lives, whichever is longer, preceding the first dose of GSK.
